Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 3
1991 3
1992 2
1993 2
1994 4
1995 1
1996 6
1997 2
1998 2
1999 1
2000 2
2001 5
2002 1
2003 3
2004 5
2005 3
2006 8
2007 8
2008 3
2009 3
2010 7
2011 9
2012 9
2013 12
2014 3
2015 3
2016 8
2017 9
2018 8
2019 2
2020 6
2021 10
2022 4
2023 4
2024 5
2025 9
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

157 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss: A Randomized Controlled Trial.
Henkel A, Johnson SA, Reeves MF, Cahill EP, Blumenthal PD, Shaw KA. Henkel A, et al. Obstet Gynecol. 2023 Jun 1;141(6):1115-1123. doi: 10.1097/AOG.0000000000005190. Epub 2023 May 3. Obstet Gynecol. 2023. PMID: 37486652 Clinical Trial.
OBJECTIVE: To assess cabergoline's efficacy at decreasing breast symptoms after second-trimester abortion or pregnancy loss. ...On day 4, mean serum prolactin level was 6.5 ng/mL (SD 2.2) for those who received cabergoline and 18.0 ng/mL (SD 5.9) for placebo (P=.049 …
OBJECTIVE: To assess cabergoline's efficacy at decreasing breast symptoms after second-trimester abortion or pregnancy loss. ...On da …
Safety of Cabergoline for Prolactinoma in Pregnancy: A Systematic Review and Meta-Analysis.
Chakraborty AM, Rastogi A. Chakraborty AM, et al. Clin Endocrinol (Oxf). 2025 Nov;103(5):633-640. doi: 10.1111/cen.15304. Epub 2025 Jul 8. Clin Endocrinol (Oxf). 2025. PMID: 40629810
INTRODUCTION: Prolactinoma is commonly treated with cabergoline, a dopamine D2 agonist. The present systematic review and meta-analysis aimed to assess the safety of cabergoline during pregnancy by examining outcomes of fetal loss, congenital malformations, preterm …
INTRODUCTION: Prolactinoma is commonly treated with cabergoline, a dopamine D2 agonist. The present systematic review and meta-analys …
Cabergoline for preventing ovarian hyperstimulation syndrome.
Tang H, Hunter T, Hu Y, Zhai SD, Sheng X, Hart RJ. Tang H, et al. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD008605. doi: 10.1002/14651858.CD008605.pub2. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2016 Nov 30;11:CD008605. doi: 10.1002/14651858.CD008605.pub3. PMID: 22336848 Updated.
Both studies had a moderate risk of bias. Oral cabergoline, 0.5 mg daily, was given as an intervention and compared with a matched placebo. ...Further research should consider the risk of administering cabergoline and the comparison between cabergoline and es …
Both studies had a moderate risk of bias. Oral cabergoline, 0.5 mg daily, was given as an intervention and compared with a matched pl …
Calcium versus cabergoline for prevention of ovarian hyperstimulation syndrome: A systematic review and meta-analysis.
Baradwan S, AlJaroudi D, Agdi M, Hafedh B, Abduljabbar HH, Sabban H, Alzawawi N, Alsaad N, Alshahrani MS, Idriss A, AlSghan R, Asiri M, Baradwan A, Edrees A, Abu-Zaid A. Baradwan S, et al. Eur J Obstet Gynecol Reprod Biol. 2024 Oct;301:1-11. doi: 10.1016/j.ejogrb.2024.07.054. Epub 2024 Jul 27. Eur J Obstet Gynecol Reprod Biol. 2024. PMID: 39084180
AIM: To conduct the first-ever systematic review and meta-analysis evaluating calcium infusion versus cabergoline in preventing ovarian hyperstimulation syndrome (OHSS) among high-risk women undergoing assisted reproductive technology. ...However, calcium infusion could po …
AIM: To conduct the first-ever systematic review and meta-analysis evaluating calcium infusion versus cabergoline in preventing ovari …
Effect of cabergoline monotherapy in Cushing's disease: an individual participant data meta-analysis.
Palui R, Sahoo J, Kamalanathan S, Kar SS, Selvarajan S, Durgia H. Palui R, et al. J Endocrinol Invest. 2018 Dec;41(12):1445-1455. doi: 10.1007/s40618-018-0936-7. Epub 2018 Aug 10. J Endocrinol Invest. 2018. PMID: 30097903
The previous surgery [odds ratio (OR) 28.4], duration of cabergoline monotherapy (OR 1.31) and maximum cabergoline dose (OR 0.19) were predictors for remission of CD. Mild and severe side effects were reported in 37.3% and 5.6% of patients, respectively, during c …
The previous surgery [odds ratio (OR) 28.4], duration of cabergoline monotherapy (OR 1.31) and maximum cabergoline dose (OR 0. …
Place of cabergoline in acromegaly: a meta-analysis.
Sandret L, Maison P, Chanson P. Sandret L, et al. J Clin Endocrinol Metab. 2011 May;96(5):1327-35. doi: 10.1210/jc.2010-2443. Epub 2011 Feb 16. J Clin Endocrinol Metab. 2011. PMID: 21325455 Review.
CONTEXT: Cabergoline is widely considered to be poorly effective in acromegaly. OBJECTIVE: The aim of this study was to obtain a more accurate picture of the efficacy of cabergoline in acromegaly, both alone and in combination with somatostatin analogs. ...The chang …
CONTEXT: Cabergoline is widely considered to be poorly effective in acromegaly. OBJECTIVE: The aim of this study was to obtain a more …
Cabergoline as a preventive migraine treatment: A randomized clinical pilot trial.
Hjelholt AJ, Bach FW, Kasch H, Støvring H, Jensen TS, Jørgensen JOL. Hjelholt AJ, et al. PLoS One. 2025 Apr 1;20(4):e0320937. doi: 10.1371/journal.pone.0320937. eCollection 2025. PLoS One. 2025. PMID: 40168298 Free PMC article. Clinical Trial.
The number of participants with episodic migraine achieving 50% reduction in monthly migraine days tended to increase after cabergoline (p = 0.07). Adverse effects were reported by seven participants on cabergoline and four on placebo, none of which were serious. …
The number of participants with episodic migraine achieving 50% reduction in monthly migraine days tended to increase after cabergolin …
Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.
De Vecchis R, Esposito C, Ariano C. De Vecchis R, et al. Herz. 2013 Dec;38(8):868-80. doi: 10.1007/s00059-013-3816-0. Epub 2013 Jun 8. Herz. 2013. PMID: 23743769
Studies had to have assessed the prevalence, odds, or risk of cardiac valve regurgitation in patients who underwent chronic treatment with cabergoline for PD or hyperprolactinemia compared with patients with the same diseases whose therapy did not include cabergoline …
Studies had to have assessed the prevalence, odds, or risk of cardiac valve regurgitation in patients who underwent chronic treatment with …
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
Inzelberg R, Schechtman E, Nisipeanu P. Inzelberg R, et al. Drugs Aging. 2003;20(11):847-55. doi: 10.2165/00002512-200320110-00006. Drugs Aging. 2003. PMID: 12964891 Review.

The reduction in risk for dyskinesia was slightly more evident for pramipexole and ropinirole (p < 0.0001) than cabergoline (p = 0.0074). Odds ratios (95% confidence intervals [CI]) relative to levodopa were 0.38 (0.19-0.78) for cabergoline, 0.25 (0.13-0.47) for

…

The reduction in risk for dyskinesia was slightly more evident for pramipexole and ropinirole (p < 0.0001) than cabergoline (p = 0

…
Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials.
Leitao VM, Moroni RM, Seko LM, Nastri CO, Martins WP. Leitao VM, et al. Fertil Steril. 2014 Mar;101(3):664-75. doi: 10.1016/j.fertnstert.2013.11.005. Epub 2013 Dec 18. Fertil Steril. 2014. PMID: 24360566 Free article.
OBJECTIVE: To evaluate the efficacy and safety of using cabergoline for reducing the risk of ovarian hyperstimulation syndrome (OHSS). DESIGN: Systematic review and meta-analysis of randomized clinical trials (RCTs). ...No studies reported congenital abnormalities. CONCLUS …
OBJECTIVE: To evaluate the efficacy and safety of using cabergoline for reducing the risk of ovarian hyperstimulation syndrome (OHSS) …
157 results